32,482 McKesson Corporation $MCK Shares Bought by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP increased its position in shares of McKesson Corporation (NYSE:MCK) by 156.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 53,198 shares of the company’s stock after buying an additional 32,482 shares during the period. McKesson accounts for 2.1% of Fulcrum Asset Management LLP’s holdings, making the stock its 4th biggest position. Fulcrum Asset Management LLP’s holdings in McKesson were worth $46,007,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Nvwm LLC lifted its position in shares of McKesson by 933.3% during the 3rd quarter. Nvwm LLC now owns 31 shares of the company’s stock valued at $26,000 after buying an additional 28 shares in the last quarter. Delos Wealth Advisors LLC acquired a new stake in McKesson in the 2nd quarter valued at $27,000. Trellis Wealth Advisors LLC purchased a new stake in McKesson in the 3rd quarter worth $32,000. Clearstead Trust LLC purchased a new stake in McKesson in the 2nd quarter worth $37,000. Finally, GK Wealth Management LLC purchased a new stake in McKesson in the 3rd quarter worth $38,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Stock Performance

Shares of MCK opened at $1,060.79 on Monday. The stock has a 50 day moving average price of $938.13 and a 200 day moving average price of $868.12. McKesson Corporation has a one year low of $723.68 and a one year high of $1,121.50. The stock has a market capitalization of $122.48 billion, a price-to-earnings ratio of 27.28, a PEG ratio of 1.97 and a beta of 0.27.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Wednesday, November 4th. The company reported $11.68 earnings per share for the quarter, beating analysts’ consensus estimates of $10.72 by $0.96. The company had revenue of $110.96 billion for the quarter, compared to analyst estimates of $109.90 billion. McKesson had a negative return on equity of 202.94% and a net margin of 1.12%. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter last year, the firm posted $9.86 EPS. On average, analysts predict that McKesson Corporation will post 46.21 earnings per share for the current year.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Stockholders of record on Tuesday, December 1st will be given a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Tuesday, December 1st. McKesson’s dividend payout ratio is 9.67%.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
• Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
• Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
• Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution

Insider Transactions at McKesson

In related news, EVP Francisco Fraga sold 650 shares of the business’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $1,102.96, for a total transaction of $716,924.00. Following the transaction, the executive vice president directly owned 4,414 shares in the company, valued at approximately $4,868,465.44. The trade was a 12.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total transaction of $98,950.95. Following the transaction, the chief accounting officer owned 521 shares in the company, valued at $464,445.45. The trade was a 17.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,161 shares of company stock valued at $2,242,515 over the last quarter. Company insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Argus lifted their target price on shares of McKesson from $850.00 to $970.00 and gave the company a “buy” rating in a research report on Thursday, September 3rd. Wells Fargo & Company upped their price target on shares of McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. Evercore restated an “outperform” rating and set a $950.00 price target (down from $1,000.00) on shares of McKesson in a research report on Thursday, August 6th. Mizuho raised their price target on shares of McKesson from $905.00 to $1,020.00 and gave the company a “neutral” rating in a research note on Tuesday, October 20th. Finally, Weiss Ratings upgraded McKesson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, September 4th. Fifteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,026.18.

McKesson Company Profile

McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.

The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.

Founded in 1833, McKesson serves customers primarily in the United States and Canada.